Small molecule XIAP inhibitors enhance TRAIL-Lnduced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma

Cancer Research

Volumn 69, Issue 6, 2009, Pages 2425-2434

  Vogler, Meike ^a   Walczak, Henning ^c   Stadel, Dominic ^a   Haas, Tobias L ^c   Genze, Felicitas ^b   Jovanovic, Marjana ^a   Bhanot, Umesh ^b   Hasel, Cornelia ^b   Möller, Peter ^b   Gschwend, Jürgen E ^b   Simmet, Thomas ^b   Debatin, Klaus Michael ^a   Fulda, Simone ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; XIAP PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL SURVIVAL; CHORIOALLANTOIS; CLONOGENESIS; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; XENOGRAFT; ANIMAL; BIOSYNTHESIS; CELL STRAIN HCT116; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVATION; HUMAN; METABOLISM; MITOCHONDRION; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CASPASE 3; DRUG SYNERGISM; ENZYME ACTIVATION; FEMALE; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; MITOCHONDRIA; PANCREATIC NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65549139431     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2436     Document Type: Article

References (39)

1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
2. Schneider G, Siveke JT, Eckel F, Schmid RM, Pancreatic cancer: basic and clinical aspects. Gastroenterology 2005;128:1606-25.
3. Gukovskaya AS, Pandol SJ. Cell death pathways in pancreatitis and pancreatic cancer, Pancreatology 2004;4:567-86.
4. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
5. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798-811.
6. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.
7. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene 2004;23:2861-74.
8. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death, Physiol Rev 2007;87:99-163.
9. LeBlanc HN, Ashkenazi A Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
10. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007;39:1462-75.
11. Salvesen GS, Duckett CS. IAP proteins: blocking the road to deaths door. Mat Rev Mol Cell Biol 2002;3:401-10.
12. Fairbrother WJ, Vucic D. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 2007;13:5995-6000.
13. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in viva. Mat Med 2002;8:808-15.
14. Vogler M, Durr K, Jovanovic M, Debatin KM, Fulda S. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007;26:248-57.
15. Oost TK, Sun C, Armstrong RC, et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer, J Med Chem 2004;47:4417-26.
16. Chao R, Deckwerth TL, Furth PS, et al., inventors; Tetrapeptide analogs. United States patent WO2006/017295A2. 2006 16.02.2006.
17. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-l/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997;57:3823-9.
18. Ehrhardt H, Fulda S, Schmid 1, Hiscott j, Debatin KM, Jeremias I. TRATL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB. Oncogene 2003;22:3842-52.
19. Mohr A, Zwacka RM, Debatin KM, Stahnke K. A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c release. Cell Death Differ 2004;11:1153-4.
20. Giagkousiklidis S, Vellanki SH, Debatin KM, Fulda S. Sensitization of pancreatic carcinoma cells for γ-irradiation-induced apoptosis by XIAP inhibition. Oncogene 2007;26:7006-16.
21. Kuefer R, Hofer MD, Altug V, et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 2004;90:535-41.
22. Ganten TM, Koschny R, Sykora j, et. al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006;12:2640-6.
23. Hasel C, Rhanot UK, Heydrich R, Strater J, Moller P. Parenchymal regression in chronic pancreatitis spares islets reprogrammed for the expression of NFκB and IAPs. Lab Invest 2005;85:1263-75.
24. Kunzi-Rapp K, Genze F, Kufer R, Reich E, Hautmann RE, Gschwend JE. Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model, J Urol 2001;166:1502-7.
25. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, editor. Synergism and antagonism in chemotherapy. San Diego (CA): Academic Press; 1991. p. 61-102.
26. Vogler M, Giagkousiklidis S, Genze F, Gschwend JE, Debatin KM, Fulda S. Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. Oncogene 2005;24:7190-202.
27. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists.J Clin Invest 2008;118:1979-90.
28. Humphreys RC, Halpern W. Trail receptors: targets for cancer therapy. Adv Exp Med Biol 2008;615:127-58.
29. Karikari CA, Roy I, Tryggestad E, et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther 2007;6:957-66.
30. Chauhan D, Neri P, Velankar M, et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007;109:1220-7.
31. Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004;5:25-35.
32. Giagkousiklidis S, Vogler M, Westhoff MA, Kasperezyk H, Debatin KM, Fulda S. Sensitization for γ-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res 2005;65:10502-13.
33. Varfolomeev E, Blankenship JW, Wayson SM, et al.
34. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 2007;131:669-81.
35. Vince JE, Wong WW, Khan N, et al. IAP antagonists target cIAPI to induce TNFα-dependent apoptosis. Cell 2007;131:682-93.
36. Gaither A, Porter D, Yao Y, et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-α signaling. Cancer Res 2007;67:11493-8.
37. Petersen SL, Wang L, Yalcin-Chin A, et al. Autocrine TNFαsignaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007;12:445-56.
38. Wang L, Du F, Wang X. TNF-α induces two distinct caspase-8 activation pathways. Cell 2008;133:693-703.
39. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science 2004;305:1471-4.